مباشر

Clinical OMICsAI Foundation Model Maps Tumor Mutations to Predict Cancer Therapy Response BioPharma DiveCardio drugmaker Kardigan plans to go public BioPharma DiveKailera’s three-pronged obesity shot shows promise in early trial BioPharma DiveApogee eczema drugs gets Blackstone backing, heads to Phase 3 Endpoints NewsAstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave Endpoints NewsApogee secures Blackstone capital to move Dupixent rival into Phase 3 Clinical OMICsPrecancerous Adenomas Alter Gut Microbiome for Long Period FierceBiotechD&D sees fibrosis improvements, MASH resolution after rolling dice on GLP-1 drug FierceBiotechInsulet issues voluntary correction for Omnipod devices in leaky insulin fault Endpoints NewsWuXi Bio signs deal to manufacture Viridian's thyroid eye disease drug Endpoints News#ASCO26: Cancer immunotherapy's magic bullet era is fading. Here's what's next Endpoints NewsBiopharma Sentiment Index | Q2 2026

FierceBiotech ٢٧ مايو ٢٠٢٦

Apogee bags $1.3B Blackstone royalty funding deal to push eczema challenger into phase 3

Apogee Therapeutics has secured a promise of up to $1.3 billion in financing from Blackstone Life Sciences as the biotech gears up to take its anti-IL-13 antibo...

Apogee Therapeutics has secured a promise of up to $1.3 billion in financing from Blackstone Life Sciences as the biotech gears up to take its anti-IL-13 antibody into phase 3.